z-logo
Premium
Third dose of COVID‐19 vaccine restores immune response in patients with haematological malignancies after loss of protective antibody titres
Author(s) -
Šušol Ondrej,
Hájková Barbora,
Zelená Hana,
Hájek Roman
Publication year - 2022
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.18073
Subject(s) - medicine , seroconversion , antibody , immunology , immune system , covid-19 , antibody response , antibody therapy , virology , monoclonal antibody , outbreak , disease , infectious disease (medical specialty)
Summary We have vaccinated 392 patients with two doses of mRNA COMIRNATY vaccine with an overall antibody response of 70% (best in cMPN, worst in CLL). We have then vaccinated 80 patients who did not achieve seroconversion or were low responders with a third dose of COMIRNATY vaccine. Our first results show promise, especially for patients on anti‐CD38 therapy.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here